The Treat and Reduce Obesity Act of 2025 expands Medicare coverage for obesity treatments, directly benefiting pharmaceutical companies producing GLP-1 agonists and medical device manufacturers. This legislation significantly increases the total addressable market for these therapies.
Impact: 7/10S1973Congressional Bill